HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.
Advertisement
Set Alert for Articles By Kate Rawson

Latest From Kate Rawson

ICER Reviews Duchenne: Exondys 51 Lacks Net Health Benefit; Emflaza Fairs Better

High price tag, thin evidence of clinical efficacy for Exondys 51 result in low score from ICER, but a re-do is almost certain when confirmatory data on eteplirsen are released.

Reimbursement Neurology

Congress’ Next Steps On REMS Abuses: Will Improving FDA-FTC Communication Help?

US FDA has seen little success in ending gaming of the patent process by brand name manufacturers. One problem: the agency’s referrals to FTC on anti-competitive cases appear go into a black box.

Generic Drugs Legal Issues

First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'

DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.
Advertising, Marketing & Sales Pricing Debate

FDA Finalizes Comparative Safety, Efficacy Requirement For New Opioids

New opioids will need to provide a “significant advantage” over approved products under new requirements that treat opioids “differently” from other drug classes, outgoing Commissioner Gottlieb says.
Neurology Drug Review

Measles Hearings Offer Counterpoint To Pricing Spotlight: Vaccines Touted As Cost-Effective Solution To Outbreaks

Congressional hearings on the recent outbreaks of measles and other vaccine-preventable diseases offered a positive theme for the industry during the ongoing drug pricing debate.

Legislation Drug Safety

Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas

Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.

Legislation Pricing Debate
See All
Advertisement
UsernamePublicRestriction

Register